10:57:03 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-10-18 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-06 X-dag ordinarie utdelning MODU 0.00 EUR
2024-04-26 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-10-20 15-10 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-03 X-dag ordinarie utdelning MODU 0.00 EUR
2023-05-02 Årsstämma 2024
2023-04-28 15-10 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-03 X-dag ordinarie utdelning MODU 0.00 EUR
2022-05-02 Årsstämma 2022


ListaFirst North Finland
Modulight är verksamt inom teknikbranschen. Bolaget designar, marknadsför och producerar biomedicinska laserprodukter som används inom onkologi, genetik och oftalmologi. Kunderna består primärt av sjukhus och företagskunder verksamma inom medicinteknik. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Störst verksamhet återfinns inom Europa.
2023-01-23 13:05:00

Modulight Corp., Company Release, Insider information, 23 January 2023 at 2.05 p.m. (EET)

Modulight Corp. has received an approval from the US Food and Drug Administration FDA for its ML6710i laser device for the treatment of wet age-related macular degeneration (AMD) in the United States, which was already expected in 2021 and discussed in the listing prospectus. The company started cooperating with Bausch + Lomb on the preparation of a marketing authorization application for the US Food and Drug Administration FDA already in 2018. Now the company has received information about the approval. The company will start launching the product in the US without delay.

The ML6710i is a new type of medical laser device designed to treat various eye diseases. It is very easy to use and works with the iPad. All operating parameters and laser usage events are securely stored in the Modulight Cloud treatment log.

In 2018, Bausch + Lomb, the world's leading company focusing on the treatment of eye diseases, and Modulight signed an exclusive cooperation agreement for the development of laser devices that work with the company's VISUDYNE® drug. VISUDYNE® is an injectable photosensitizer for the treatment of patients with choroidal neovascularization due to age-related macular degeneration (AMD) or other causes. The VISUDYNE® drug is activated with Modulight ML6710i Laser.

"Modulight works closely with healthcare companies to tailor its wide range of laser technology solutions to meet their needs in particular. Our collaboration with Bausch + Lomb has continued for several years, and together we have succeeded in developing a top-class laser. Now that we have received approval in the US market, we will be able to bring this product on sale”, commented Modulight’s CEO Seppo Orsila.

Modulight has submitted the product's marketing authorization application also in the European Union, where the authorization is expected this year.

VISUDYNE® is a registered trademark of Novartis AG, used under license. All other product/brand names and/or logos are trademarks of their respective owners.


For further information, please contact:

CEO Seppo Orsila m. +358 40 830 4671
IR Ulla Haapanen m. +358 40 830 4676
Email: ir@modulight.com

Certified Adviser: Danske Bank A/S, Finland Branch, m. +358 40 414 5358
Twitter: @modulight

Modulight in brief

Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. 

Follow Modulight: Twitter LinkedIn | Facebook | YouTube | Instagram | #killcancer #laserfamily